Nina Shah, MD
Internal Medicine · San Francisco, CANPI 1063692614
Payments from drug & device makers
Across 237 payments — averaging $22,592 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$3.4M
- Janssen Research & Development, LLC$1.6M
- AbbVie$155K
- Sanofi$52K
- GSK$42K
- Genentech, Inc.$40K
- plus $87K from 17 others
Across 1 payment — averaging $4145.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 32 | $3,364,536 |
| Janssen Research & Development, LLC | 94 | $1,613,488 |
| AbbVie | 6 | $155,042 |
| Sanofi | 25 | $52,436 |
| GSK | 24 | $42,461 |
| Genentech, Inc. | 6 | $39,780 |
| Karyopharm Therapeutics Inc. | 12 | $24,741 |
| AstraZeneca | 2 | $23,290 |
| Pfizer | 7 | $11,063 |
| CSL Behring | 1 | $6,482 |
| Amgen | 5 | $5,124 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,525 |
| Gilead | 3 | $4,403 |
| Merck | 1 | $3,355 |
| Epizyme, Inc. | 1 | $1,500 |
| Janssen Global Services, LLC | 1 | $620 |
| Menarini Silicon Biosystems, Inc. | 1 | $500 |
| Seagen Inc. | 4 | $350 |
| Johnson & Johnson | 4 | $273 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
| Vifor Pharma, Inc. | 1 | $82 |
| Daiichi Sankyo Inc. | 1 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
How this compares
$5,354,299 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
- John FahySan Francisco$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.